Hints and tips:
Related Special Reports
...The New York-based pharma group has acquired four companies — Arena, ReViral, Biohaven and Global Blood Therapeutics — that it expects will contribute about $10bn in revenues in 2030....
...Here’s how it worked: Signa Development, one of three companies that oversaw the group’s investments, lent €125mn to Laura Finance Holding GmbH and another €190mn to Laura Holding GmbH, as part of large...
...Pfizer spent $6.7bn on Arena Pharmaceuticals in December, lured by its medicines for immune-inflammatory diseases, and paid $2.3bn in August last year for Trillium Therapeutics as it targeted treatments...
Pharmaceutical groups to part ways with longstanding executives
...In that arena, US law has proved to be an efficient, if controversial, method for resolving disputes, allowing victims to get their economic redress while letting underlying businesses get out from underneath...
...Sector expertise Sectors listed: aerospace & defence; automotive; chemicals & pharmaceuticals; construction & infrastructure; consumer goods & retail; energy, utilities & environment; financial institutions...
...It has also acquired several biotech companies with drug candidates in late-stage development, including Biohaven Pharmaceuticals and Arena Pharmaceuticals....
...The US drugmaker has spent almost $30bn on acquisitions over the past two years, snapping up Arena Pharmaceuticals, Biohaven Pharmaceuticals, Global Blood Therapeutics, ReViral and Trillium Therapeutics....
...CureVac is suing fellow German pharmaceutical company BioNTech, alleging that the Covid-19 vaccine maker infringed vital patents relating to messenger RNA technology....
...Compared with other arenas, science has been slow to address these inequalities, and scientific discovery can take decades....
...But in areas like pharmaceuticals, very little progress has been made to diversify flows (a 2021 White House supply chain review noted extreme concentration in pharmaceutical ingredients)....
...It also recently completed a $6.7bn deal to buy Arena Pharmaceuticals, a biotech developing medicines targeting immune-inflammatory diseases in the areas of gastroenterology and cardiology....
...Pfizer has struck a $6.7bn deal to buy Arena Pharmaceuticals, a company developing treatments for several immuno-inflammatory diseases....
...And in the outsourcing arena, Capita and Serco are representing....
...“The next test case many of us are watching is Pfizer’s acquisition of Arena Pharmaceuticals,” says Loncar....
...So has the sense that the EU has been too squishy in the past when protecting its core interests in the international trade arena....
...What has driven her into the public arena is a conviction that the world might be sleepwalking into a fertility crisis....
...Michela Tindera That’s Jamie Smyth, the FT’s US pharmaceutical correspondent....
New mRNA technology could make jabs better-matched to different annual strains and improve efficacy
...With ample state funding, the small mRNA company chose to go it alone in developing a coronavirus vaccine instead of teaming up with a major pharmaceutical partner....
Results of animal study show success in tackling several coronavirus variants
...But this depends on the approach regulators ultimately adopt towards dealmaking, with Pfizer’s $6.7bn takeover of Arena Pharmaceutical, which was announced earlier this month, set to become a test case....
...The UK pharmaceutical company decided to supply the adjuvant rather than create its own vaccine from scratch in the hope of having more chances of success....
The mRNA pioneer was beaten by Moderna and BioNTech but is plotting a comeback
International Edition